Yu and colleagues reported that cardiac and circulatory expressions of irisin were increased in cardiac hypertrophy mice, and the treatment of irisin is able to inhibit pathological cardiac hypertrophy and fibrosis through AMPK-mammalian target of rapamycin (mTOR) signaling pathways (79). The gene discussed is FNDC5; the disease is cardiac hypertrophy.